Sobrera Pharma AB, a Swedish pharmaceutical company developing therapies for treatment and prevention of Alcohol Use Disorder (AUD), today announced successful results from a Phase 2 trial [...]
The United States Patent and Trademark Office (USPTO) has granted a new patent US 11,318,143 further strengthening the Company’s Intellectual property position and coverage for the Company’s [...]
Click below to read the presentation. Sobrera Update June 2021
Sobrera Pharma AB is pleased to announce the Decisions to Grant on the European patent 3582764 titled ’Treatment of Alcohol Use’ by the European Patent Office (EPO). The decision to grant on the [...]
Recruitment of patients to the phase II study (COMB study) is ongoing at the clinical study site in Gothenburg and in Stockholm. The study team is sharing information about the study including [...]
Sobrera Pharma AB announces 28 MSEK capital raise through a directed share issue to finance the continued development of SO-001, a new oral therapy for patients with Alcohol Use Disorder (AUD). [...]
We're not around right now. But you can send us an email and we'll get back to you, asap.
Start typing and press Enter to search